Livforsakringsbolaget Skandia’s 10x Genomics TXG Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,000	Closed	-$76K	–	619
2022 Q1	$76K	Hold	1,000	–	–	0.01%	581
2021 Q4	$149K	Hold	1,000	–	–	0.01%	538
2021 Q3	$146K	Hold	1,000	–	–	0.01%	557
2021 Q2	$196K	Hold	1,000	–	–	0.01%	553
2021 Q1	$181K	Hold	1,000	–	–	0.01%	489
2020 Q4	$142K	Buy	+1,000	New	+$145K	0.01%	517

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Livforsakringsbolaget Skandia's TXG Position: Q2 2022 in Review

Livforsakringsbolaget Skandia sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 1,000 shares — an estimated $76K sold.

Livforsakringsbolaget Skandia first reported a position in TXG in Q4 2020 and held it in 6 quarters. The position peaked at $196K in Q2 2021. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

Livforsakringsbolaget Skandia reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
Livforsakringsbolaget Skandia sold 1,000 10x Genomics shares in Q2 2022, an estimated $76K.
Livforsakringsbolaget Skandia first reported a position in 10x Genomics in Q4 2020 and held it in 6 quarters.
Livforsakringsbolaget Skandia's 10x Genomics position peaked at $196K in Q2 2021.
254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Livforsakringsbolaget Skandia's 13F filing for Q2 2022, filed 16 Aug 2022.